Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-12-06 pm EST 5-day change 1st Jan Change
59.38 USD +0.92% Intraday chart for Bristol-Myers Squibb Company +0.27% +15.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nuvig Therapeutics, Inc. announced that it has received $161 million in funding from a group of investors Dec. 04 CI
Bristol-Myers Seeks Bolt-On Acquisitions Dec. 03 CI
Bristol-Myers Squibb Company Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:00 AM Dec. 03
AI Proteins, Inc. Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued Up to $400 Million Dec. 03 CI
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List Nov. 29 MT
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating Nov. 25 MT
Wall Street warms to AI's glow Nov. 22Our Logo
Bristol Myers: presents new data to ASH Nov. 19 CF
Bristol Myers Squibb?s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms Nov. 19 CI
Bristol-Myers Squibb Company Presents at Jefferies London Healthcare Conference 2024, Nov-19-2024 09:30 AM Nov. 19
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight Nov. 18 MT
HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating Nov. 15 MT
Bristol-Myers Says European Committee Recommends Approval of Opdivo-Yervoy Combination Therapy for Colorectal Cancer Nov. 15 MT
Bristol Myers Squibb's Augtyro Recommended for EU Approval Nov. 15 MT
Bristol Myers: positive opinion from CHMP for Opdivo Nov. 15 CF
Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug Nov. 15 DJ
Bristol-Myers Says European Committee Recommends Approval of Repotrectinib Nov. 15 MT
Bristol Myers: positive opinion for repotrectinib in U Nov. 15 CF
Bristol-Myers Squibb Faces $6.7 Billion Lawsuit in Renewed Cancer Drug Delay Case Nov. 15 MT
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors Nov. 15 CI
JPMorgan Adjusts Price Target on Bristol-Myers Squibb to $70 From $64, Keeps Overweight Rating Nov. 13 MT
Analyst recommendations: Spotify, Starbucks, Tesla, Block, Coinbase... Nov. 13Our Logo
Daiwa Upgrades Bristol-Myers Squibb to Outperform From Neutral, Adjusts Price Target to $65 From $50 Nov. 13 MT
UBS Raises Bristol-Myers Squibb Price Target to $60 From $54, Maintains Neutral Rating Nov. 12 MT
With Trump, market mayhem meets Bitcoin boom Nov. 12Our Logo
Chart Bristol-Myers Squibb Company
BMY: Dynamic Chart
Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Employees
34,100
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
surperformance-ratings-light-chart BRISTOL-MYERS-SQUIBB-COMPMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
59.38USD
Average target price
60.43USD
Spread / Average Target
+1.78%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. News Bristol-Myers Squibb Company
  5. Bristol-Myers Squibb Adds $3 Billion to Buyback Program